Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Immunotherapy Plus Anlotinib in Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07830355Phase 2Not yet recruiting
- Sponsor
- Shanghai Chest Hospital
- Start
- Sep 2026
- Primary completion
- Dec 2028
01
Overview
A Phase 2 trial of anlotinib in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Shanghai Chest Hospital. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
anlotinib
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07830355.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07830355.